Kornimate/medical-research-clean huggingface dataset:
evaluating the relationship between tobacco use, anxiety sensitivity, and panic in adolescents

Conditions: Panic Disorder

Summary: this study will determine whether there is a relationship between tobacco use and a heightened response to panic-producing events among adolescents. this study is fundamental research. it was not a clinical trial.

growing up is hard enough, and adolescence can be a particularly stressful time in people's lives as they adjust to the transition from childhood to adulthood. peer pressure can add to this anxiety, making it more likely for teens to take part in risky behaviors such as smoking cigarettes. every day, more than 4,000 teens smoke their first cigarette and nearly half of those teens will become regular, daily smokers. cigarette smoking is associated with a multitude of health risks, including an increased likelihood of experiencing panic attacks, anxiety disorders, and depression. this study will evaluate a group of teens, ranging from those who have never smoked to those who smoke daily, to determine whether there is a relation between adolescent smoking history and their vulnerability to panic-producing situations. participants in this study will undergo a brief medical screening, followed by a short interview that will include several questionnaires regarding emotions, experiences, and personal habits. participants will then attend a series of laboratory assessments for 1 hour. the first assessment will include a 3-minute voluntary hyperventilation procedure in which participants will be directed when to breathe in and when to breathe out, at a faster rate than normal. participants will then take part in two computerized tasks: one will be a computerized task that involves blowing up a balloon and deciding when to quit before the balloon pops; the other task will involve choosing hypothetical amounts of money now or after a period of delay. during the laboratory assessments, all participants will have electrodes attached to their bodies and sensors around their chests to measure heart rate, palm sweating, and muscle tension. results from this study will be used to evaluate the association between smoking and increased panic levels under stressful conditions among adolescents.

Eligibility criteria:
inclusion criteria: * adolescents, ranging from those who have never smoked to those who smoke daily exclusion criteria: * current or past diagnosis of a panic disorder * acute or chronic cardiopulmonary or respiratory illness (e.g., asthma or bronchitis) * pregnant

Keywords: cigarette smoking tobacco use adolescents anxiety sensitivity (as)
study of gemcitabine plus nab-paclitaxel versus s1 plus nab-paclitaxel in metastatic adenocarcinoma of the pancreas

Conditions: Pancreatic Cancer; Nab-paclitaxel; Gemcitabine; S1

Summary: a randomized multi-center phase ii trial of nab-paclitaxel in combination with gemcitabine verus s1 with gemcitabine as first-line treatment for locally advanced or metastatic pancreatic cancer

a phase ii, open-label randomized, multicenter trial to compare nab-paclitaxel in combination with gemcitabine verus s1 with gemcitabine with respect to overall survival, objective tumor response rate and progression free survival (pfs) in patients diagnosed with locally advanced or metastatic adenocarcinoma of the pancreas.

Eligibility criteria:
inclusion criteria: * histological or cytological confirmation of pancreatic adenocarcinoma * distant metastatic or unresctable locally advanced diseases * ctscan (or mri if scanner contraindicated) completed within 3 weeks of the start of treatment * at least one lesion measurable by recist v1.1 criteria * life expectancy\> 3 months * no previous chemotherapy (adjuvant chemotherapy with gemcitabine authorised if administered more than 6 months prior to inclusion) * no previous radiotherapy (unless at least one measurable target lesion outside the irradiation zone) * pain must be monitored before inclusion * 18 years \< age \< 70 * performance status: 0-1 * anc ≥ 1500/mm3, platelets ≥ 100 000/mm3, haemoglobin ≥ 9 g/dl * asat (sgot), alat (sgpt) ≤ 2.5 x uln or ≤ 5 x uln if liver metastases found * bilirubin ≤ 1.5 x uln (patients drained by retrograde technique are includable), * creatinine \ 60 ml/min * patient information and signature of informed consent exclusion criteria: * concurrent other effective treatment (including radiotherapy) * resectable patients * allergy history to other drugs in the same class patients with pregnancy or lactation * known severe internal medical diseases * abnormal heart function or relevant history of myocardial infarction and severe arrhythmia * immunocompromised patients, such as hiv positive * uncontrollable mental illness * other conditions the researchers considered ineligible for the study

Keywords: pancreatic cancer nab-paclitaxel gemcitabine s1
evaluation by oncologists of strategies for the prevention and treatment of chemotherapy-induced peripheral neuropathies

Conditions: Chemotherapy-induced Peripheral Neuropathy

Summary: chemotherapy induced peripheral neuropathy (cipn) is one of the most deleterious adverse effect of neurotoxic anticancer drugs affecting up to 40% of patients. these neurotoxic anticancer agents include mainly: cisplatin (bronchopulmonary cancers), oxaliplatin (colorectal cancers), paclitaxel (breast cancers and bronchopulmonary cancers), docetaxel (breast cancers and bronchopulmonary cancers) and bortezomib (multiple myeloma). cipn affects not only the quality of life of patients, it also has a major impact on oncology strategy, forcing oncologists to reduce dose-intensity, to stop an ongoing chemotherapy regimen and to change therapeutic strategies, with a risk of compromising patients' survival. there is no real preventive or curative treatment (except duloxetine) for cipn and it is not known what is the practice of oncologists in france? however, it is essential to know the degree of sensitivity of oncologists to this problem and their practice. with this study, the investigators propose to assess the current practices of management by oncologists in france in 2019, for any type of practitioners of university hospital, or general hospital, for all type of neurotoxic anticancer drugs.

this observational and cross-sectional study will be conducted as a survey using the redcap software and the response to this survey will be done online, in real time, with an automatic, secure and centralized data collection (chu clermont-ferrand). french oncologist will be contacted by email thanks to the regional cancer networks. answer to the survey will be done online.

Eligibility criteria:
inclusion criteria: * oncologist exclusion criteria: * pain physician

Keywords: peripheral nervous system diseases oncologists
effect of music on burden of dental implant surgery

Conditions: Personalized Musical Intervention

Summary: personnalized music can decrease the burden of care. this experimental clinical trial examines the effect of personalized musical intervention on the burden of dental implant surgery. the intervention consists of a personnalized musical intervention and the control group consists of audio books. the burden of dental implant surgery will be defined by a composite variable including surgical pain, state anxiety and dissatisfaction with dental implant surgery.


Eligibility criteria:
inclusion criteria: patients included in the study: * will have an adequate understanding of the french or english language both written and spoken, * will have the physical and psychological ability to understand and complete the questionnaires used in the study, * will consent to follow research instructions, * will consent to follow the allocated sequence of interventions without prior notification, * will undergo a dental implant surgery not exceeding 2 hours, exclusion criteria: patients : * do not have the necessary clinical criteria to receive implants. * have an implant surgical treatment that would increase treatment time beyond 2 hours, * have a history of neurological disorders, diagnosed with severe psychiatric disorders (e.g. schizophrenia, bipolar disorder), substance abuse * have a major diagnosed hearing problem.

Keywords: personalized musical intervention experimental study dissatisfaction anxiety surgical pain burden of care pilot randomized controlled trial
effect of fosaprepitant on motor evoked and somatosensory evoked potentials under general anesthesia

Conditions: Postoperative Nausea

Summary: the purpose of this study is to determine if intravenous fosaprepitant can interfere with nervous system monitoring signals in patients having surgery under general anesthesia. this medication has numerous effects on the sensory nerve transmission which can theoretically have effects on the ability to accurately measure somatosensory evoked potentials.

the purpose of this study is to determine if intravenous fosaprepitant can interfere with nervous system monitoring signals in patients having surgery under general anesthesia. fosaprepitant is a drug commonly used to prevent post-operative nausea and vomiting, and works by inhibiting "substance p", which is found in the brain and spinal cord. theoretically, fosaprepitant could interfere with nervous system recordings because of its effect on substance p,but it is not known if this actually occurs. the drug will be given after the patient has been anesthetized but before surgical incision so that if there are any changes on the intraoperative neuromonitoring signals they can only be attributed to fosaprepitant. if fosaprepitant alters intraoperative neuromonitoring signals during surgical procedures under general anesthesia, it would be important because anesthesiologist's who administer this drug would want to give it at the beginning of surgery when changes in intraoperative neuromonitoring signals would be unlikely to mean that these changes were due to surgical damage to the nervous system.

Eligibility criteria:
inclusion criteria: * having a surgical procedure requiring general anesthesia, having a surgical procedure where neuromonitoing with somatosensory evoked potentials and motor evoked potentials neuromonitoring is requested by the surgical team exclusion criteria: * patient refusal, allergy to the drug or any of its excipients, pre-operative motor or sensory deficit
a study of ngm282 in patients with primary sclerosing cholangitis

Conditions: Primary Sclerosing Cholangitis

Summary: the purpose of this study is to determine the safety, tolerability, and activity of ngm282 in patients with primary sclerosing cholangitis.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of psc exclusion criteria: * clinically significant acute or chronic liver disease of an etiology other than psc * secondary or igg4 related sclerosing cholangitis
impact of patient support by the medical staff on adherence to therapy with pegintron plus rebetol (study p04413)

Conditions: Hepatitis C; Chronic Hepatitis C

Summary: the objective of this study is to assess the impact of participant care and support on treatment adherence. pegintron pen and rebetol will be administered to participants with hepatitis c virus (hcv) in accordance with approved labeling. sites will be categorized as providing high vs low level of participant management based on information about the level of participant support and management captured on the site questionnaire. data on each participant will be collected by a physician on an electronic participant case report form (crf) and by the participant via a questionnaire. treatment completion rates will be analyzed based on the high vs low level of participant management. the hypothesis is that physicians investing more time and effort into participant management achieve higher treatment completion rates among their hepatitis c patients than physicians offering less participant management measures.


Eligibility criteria:
inclusion criteria: * participants with chronic hepatitis c. those participating in patient assistance programs during therapy for hepatitis c. exclusion criteria: * participants who have previously been treatment for hepatitis c (non-naïve) other exclusion criteria as described in local summary of product characteristics (spc).
transcricoid injection vs. spray as you go method for local anaesthesia during ebus-tbna

Conditions: Pulmonary Disease

Summary: endobronchial ultrasound guided transbronchial needle aspiration (ebus -tbna) is commonly performed for diagnosis of mediastinal pathologies. the procedure can either be performed under general anaesthesia or under moderate sedation with topical anaesthesia. most patients tolerate the procedure well although cough is often reported as a distressing symptom. topical lignocaine is administered during endobronchial ultrasound for local anaesthesia. there is limited literature on the efficacy of transtracheal/transcricoid injection versus spray as you go method for lignocaine delivery to the airways during ebus-tbna. this study would help to determine the procedure comfort for the patient while using the transtracheal/transcricoid method vs the spray as you go method.

for all patients meeting the inclusion criteria, the demographic profile including age, sex, weight, smoking history shall be recorded. a written informed consent will be obtained from all participants. the patients who undergo ebus-tbna under moderate sedation would be randomised in a one is to one ratio either to transcricoid injection or spray as you go lignocaine group. prior to ebus-tbna, blood pressure, pulse rate, respiratory rate and pulse oximetry saturation will be recorded at the baseline patients in both the groups shall be prepared in a similar fashion except for the use of transcricoid injection in one group. during the procedure, 2 ml aliquots of 1% lignocaine solution will be delivered through the bronchoscope when using spray-as-you go technique. patients in the transcricoid group shall initially receive 5 ml of 2% lignocaine solution and additional aliquots of 1% lignocaine using the spray as you go method. the total lignocaine dose during the procedure will be recorded. the patients would be monitored for any adverse effects throughout the procedure. the bronchoscopist doing the procedure will be provided vas charts to mark the severity of cough and overall procedure satisfaction. an audio recorder shall be used to record the cough count during the entire procedure. post procedure, patients will record the pain experienced while undergoing the procedure on the vas scale.

Eligibility criteria:
inclusion criteria: * indication for ebus tbna * age \> 18 years exclusion criteria: * refusal of consent * known documented hypersensitivity to lignocaine * procedure performed under general anaesthesia * pregnancy * hypoxemia (oxygen saturation \[by pulse oximetry\] \< 92% with fio2 of ≥ 0.3 * bronchoscopy done through endotracheal or tracheostomy tube * midline neck mass or thyroid enlargement making the identification of * cricothyroid membrane difficult' * patients with central airway obstruction * patients with active ongoing hemoptysis

Keywords: bronchoscopy lignocaine endobronchial ultrasound
post-marketing study to assess complication rates of oncology patients with ports and peripheral ivs

Conditions: PORTs/Peripheral IVs Complication Rates

Summary: this study is to collect current information on complications rates of subjects undergoing chemotherapy administration through ports and peripheral ivs.


Eligibility criteria:
inclusion criteria: * male or female, age ≥ 21 years * subject is currently undergoing or has had infusional cancer therapy (solid tumor or hematologic) through a bard port with a distally-valved catheter/open-ended catheter or infusion through a piv * subject had a chemotherapy regimen consisting of a vesicant and/or irritant * subject has signed an informed consent form (icf) or has had an icf signed by the subject's legally authorized representative exclusion criteria: * subject has/had an implanted non bard port

Keywords: port peripheral intravenous lines oncology
concurrent chemoradiotherapy combined with immunotherapy in patients with potentially resectable pancreatic cancer

Conditions: Pancreatic Carcinoma

Summary: the objective of this study is to evaluate the efficacy and safety of concurrent chemoradiotherapy combined with immunotherapy in patients with potentially resectable pancreatic cancer.

due to the hidden onset and rapid progression of pancreatic cancer, most patients are already locally advanced or have distant metastasis at the time of diagnosis and lose the opportunity for surgery. even among operable patients, about 50% will have recurrence and metastasis one year after surgery. therefore, more and more evidence supports neoadjuvant therapy for patients with high risk factors for resectable pancreatic cancer, and conversion therapy followed by surgery for patients with borderline resectable and locally advanced pancreatic cancer. therefore, the objective of this study is to evaluate the efficacy and safety of concurrent chemoradiotherapy combined with immunotherapy in patients with potentially resectable pancreatic cancer.

Eligibility criteria:
inclusion criteria: 1. age \>= 18 years； 2. eastern cooperative oncology group (ecog) score of 0-1; 2. pancreatic cancer confirmed by histology or cytology; 3. potentially resectable pancreatic cancer documented by contrast enhanced ct (or mri) scan; 4. hematological indexes: neutrophil count \>= 1.5 x 10\^9/l hemoglobin \>= 10g / dl platelet count \>= 100 x 10\^9 / l 5. biochemical indicators: total bilirubin \ = 60ml / min. 6. participants of childbearing age need to take appropriate protective measures (contraceptive measures or other methods of birth control) before entering the group and during the test: 7. signed informed consent; 8. follow the protocol and follow-up procedures. exclusion criteria: 1. have received systematic anti-tumor treatment. 2. previous history of other tumors, except for cervical cancer in situ, treated squamous cell carcinoma or bladder epithelial tumor (ta and tis) or other malignant tumors that have received radical treatment (at least 5 years before enrollment). 3. active bacterial or fungal infection (\> = level 2 of national cancer institute common toxicity criteria (nci-ctc), version 3.0). 4. human immunodeficiency virus (hiv), hepatitis c virus (hcv), hepatitis b virus (hbv) infection, uncontrollable coronary artery disease or asthma, uncontrollable cerebrovascular disease or other diseases considered by researchers to be out of the group. 5. autoimmune diseases or immune defects who are treated with immunosuppressive drugs. 6. pregnant and lactating women. pregnant women of childbearing age must be tested negative within 7 days before entering the group. 7. drug abuse, clinical or psychological or social factors make informed consent or research implementation affected. 8. allergic to programmed cell death protein-1 (pd-1) monoclonal antibody immunotherapy drugs.
promoting patient-centered counseling to reduce inappropriate diagnostic tests

Conditions: Unnecessary Procedures; Low Back Pain; Osteoporosis; Headache; Magnetic Resonance Imaging; Primary Care

Summary: in this study, the investigators will develop and evaluate a novel intervention using standardized patients (sps) -- or actors playing the roles of patients -- to enhance physicians' patient-centered counseling skills regarding two frequently overused, potentially inappropriate services in primary care: magnetic resonance imaging (mri) for acute low back pain and bone densitometry in women at low-risk for osteoporosis. the investigators will further evaluate whether intervention effects on physician patient-centeredness generalize to counseling regarding other costly, unnecessary diagnostic tests.


Eligibility criteria:
inclusion criteria: * resident physician in family medicine or internal medicine who deliver primary care at one of two hospital-based primary care clinics at the university of california, davis medical center sacramento exclusion criteria: * anticipated graduation in less than one year from enrollment.
secondary prophylaxis after variceal bleeding in non-responders

Conditions: Gastrointestinal Hemorrhage; Portal Hypertension; Cirrhosis

Summary: controlled and randomized study comparing combined treatment (nadolol and endoscopic ligation) versus nadolol associated with isosorbide mononitrate or prazosin according to hemodynamic response, in the prevention of esofagic verices rebleeding.

the present is a prospective, randomized, open label study, in parallel groups, in which the patients with hemorrhage caused by esofagic varices will be randomized in two groups of treatment, after control of acute hemorrhage. all the patients included will receive standard medical treatment with beta - blockers and endoscopic ligation of the esofagic varices. the control group will be constituted by the patients assigned to receive endoscopic ligation and nadolol (n). the experimental group will be constituted by patients assigned to receive treatment according to the hemodynamic response. all patients included in the experimental group will receive pharmacologic treatment with nadolol combined with isosorbide mononitrate (mni) or prazosin (pz). in both groups it will practice a basal hepatic hemodynamic study in the 4th-5th day after their admitance (after achieve hemodynamic stability for at least 48 h and with hemorrhage controlled) and a second control hepatic hemodynamic study 3-4 weeks after the beginning of the pharmacologic treatment, once adjusted doses. in the experimental group, the responders to n + mni will keep on this treatment, but nonrespondent in the hemodynamic study will switch treatment to n + pz and a third hepatic hemodynamic study will be performed 3 to 4 weeks after the dosage adjustement. the randomization will be stratified according to the degree of hepatic failure measured by child-pugh classification (classes a and b versus c) the design is random to avoid bias in the selection of the patients.

Eligibility criteria:
inclusion criteria: * any patient with endoscopically assessed variceal bleeding (esofagic and gastric) * cirrhosis * patient agreement to be included in the study onsentiment signed exclusion criteria: * any associated comorbidity with life expectancy lesser than 6 months * patient refusement to be included in the study. * pregnancy * failure to control acute bleeding * previous prophylaxis treatment

Keywords: variceal bleeding secondary profilaxis hemodynamic portal hypertension